Fiera Capital Corp Trims Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Fiera Capital Corp reduced its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 3.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 845,732 shares of the company's stock after selling 29,861 shares during the quarter. Fiera Capital Corp owned 1.69% of Immunocore worth $26,328,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after purchasing an additional 109,206 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Immunocore by 69.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after acquiring an additional 3,053 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after acquiring an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore in the 3rd quarter worth about $218,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Immunocore in the 2nd quarter worth about $3,686,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IMCR. Morgan Stanley dropped their price objective on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Oppenheimer reaffirmed an "outperform" rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. Needham & Company LLC reduced their target price on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a report on Thursday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Immunocore in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and an average target price of $73.73.

Immunocore Stock Performance

IMCR stock traded up $0.38 during midday trading on Friday, hitting $34.69. 199,471 shares of the stock traded hands, compared to its average volume of 236,184. The stock's fifty day simple moving average is $32.64 and its 200-day simple moving average is $39.52. Immunocore Holdings plc has a 1-year low of $29.72 and a 1-year high of $76.98. The firm has a market cap of $1.74 billion, a P/E ratio of -36.52 and a beta of 0.72. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.98%. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the business earned ($0.59) earnings per share. The company's revenue for the quarter was up 23.7% compared to the same quarter last year. On average, analysts expect that Immunocore Holdings plc will post -1.71 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.